– USA, OH – Athersys, Inc. (Nasdaq: ATHX), an international, late-stage, regenerative medicine company, today announced the appointment of Dan Camardo to its Board of Directors as CEO, effective February 14, 2022, replacing interim CEO William Lehmann who will continue to serve as COO.
“It’s with great excitement today that the Board announces Daniel Camardo as the new CEO of Athersys. We are confident that Dan is the right person to lead Athersys as the Company moves forward towards the commercialization of Multistem. He brings a wealth of knowledge and a proven track record of product development, commercialization, and overall business strategy. Dan’s extensive industry experience includes transforming single product start-ups into high-functioning multi-franchise organizations, business development and alliance management. His breadth of skills and experience combined with his respected leadership and team-building style will be invaluable to Athersys as the Company enters the next exciting phase of its evolution,” said Board Chairman, Dr. Ismail Kola.
About Daniel A. Camardo
Daniel Camardo is a senior pharmaceutical and biotech executive with more than 25 years of commercial leadership experience. As CEO, he will lead Athersys forward to complete the development, approval, launch, and commercialization of the Company’s MultiStem cell therapy for the treatment of serious conditions, including ischemic stroke.
Mr. Camardo currently serves as EVP and Head of the Rare Disease and Inflammation Business Units and President, U.S. at Horizon Therapeutics (Horizon), where he has led a broad commercial transformation and built out new capabilities to support a portfolio of products in the rare disease and specialty medicines space. Before this, he led commercial operations for Horizon and helped transform the small specialty products company into a global biotechnology company focused on rare, autoimmune, and severe inflammatory diseases. He has worked in commercial leadership roles for other biotechnology and pharmaceutical companies, including Astellas, where he helped build a commercial business from U.S. market entry to more than $3.5 billion in annual net sales driven by a portfolio of specialty and rare disease medicines. Mr. Camardo has been involved in more than 10 medicine launches across various therapeutic areas, including small molecules and biologics. Mr. Camardo is recognized for creating innovative solutions to overcome marketplace challenges and fostering cross-functional collaboration to drive results.
“I am thrilled to be joining Athersys at this pivotal time. The Company and its MultiStem product have tremendous potential to help patients in a number of serious diseases with significant unmet needs I look forward to working closely with the Board, executive leadership, and Athersys employees to commercialize MultiStem and build the Company into a global leader in cell therapy and regenerative medicine,” said CEO, Dan Camardo.
Mr. Camardo holds a Bachelor of Arts degree in Economics and Mathematics from the University of Rochester and a Master of Business Administration from Northwestern University’s Kellogg School of Management.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.
For more information: https://www.athersys.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
